about
sameAs
Inhibitory mechanism of a cross-class serpin, the squamous cell carcinoma antigen 1Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesityStructural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug targetThe squamous cell carcinoma antigen 2 inhibits the cysteine proteinase activity of a major mite allergen, Der p 1The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingTowards engineering hormone-binding globulins as drug delivery agentsFrog albumin is expressed in skin and characterized as a novel potent trypsin inhibitorTargeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodiesNeutrophil elastase in cyclic and severe congenital neutropenia.Nematode sperm maturation triggered by protease involves sperm-secreted serine protease inhibitor (Serpin).Innate immune responses of a lepidopteran insect, Manduca sexta.An unusual subtilisin-like serine protease is essential for biogenesis of quinohemoprotein amine dehydrogenase.Innate immune activation in neonatal tracheal aspirates suggests endotoxin-driven inflammation.ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiologyPurification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1.Protein metamorphosis: the two-state behavior of Mad2.Regulation of poliovirus 3C protease by the 2C polypeptideBiochemical and Bioinformatic Characterization of Type II Metacaspase Protein (TaeMCAII) from Wheat.Comparative structural modeling and inference of conserved protein classes in Drosophila seminal fluid.Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.Proteinase inhibition by proform of eosinophil major basic protein (pro-MBP) is a multistep process of intra- and intermolecular disulfide rearrangements.Inhibition of proteolysis by the proform of eosinophil major basic protein (proMBP) requires covalent binding to its target proteinase.Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents.Mutational analysis of plasminogen activator inhibitor-1.Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.Mechanism-based inhibition of an aldolase at high concentrations of its natural substrate acetaldehyde: structural insights and protective strategiesHuman kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins
P2860
Q24318950-46123AD6-AA59-4A68-9EE1-72A238372F3FQ24532873-90B804D6-0FF8-458E-8D92-35673AC628AFQ27642881-9F79ADBC-9ED8-4FAA-85A1-0ECCC92766ACQ28186148-79BBF279-41EB-4D8E-BE1D-2CBBAB10846BQ28257803-861DA7CB-E4F0-445F-A5E1-ECBF54E6FEB8Q28545213-0D6DAE5A-DD4C-42B4-8670-A4BB452D0E55Q33221142-3846BED7-378C-4A38-998A-B59BD7B0182EQ35431906-018B74EC-B473-41B6-8D61-56B1187A3808Q35642863-5B0E1D22-A1D1-46F0-95E5-E7FC3B45B97DQ35749781-E92292EA-B1BD-4EFA-9168-F99E6D28B854Q35806856-80B66383-E520-472A-81A5-0AB78E9B1323Q35838860-5CE280F7-7004-469B-AD9D-81F69621279DQ36121600-B8FF959F-F751-47B8-89D0-8448160F1FD6Q36573828-071C59ED-7214-4208-8088-7C0AD97F74A6Q36842289-1B80D64D-5A35-4B29-B408-2DE5BF717897Q37101664-4304CCEA-8768-4CCE-A73E-EE15C9D5E35EQ37348188-D9ECB04F-4CFD-40B0-9606-B26FBAD18A6CQ37436714-3C7C5521-0537-42C7-9ADF-CB80A08CF427Q37533771-540E282B-BCF7-45AB-93E8-E15036BD6F14Q38132176-0AC05646-5F89-4B5D-91CC-85F58EB78A69Q39194903-F25C9836-5BB8-4AD3-A2E6-6726975A98BAQ40472377-525EECFC-0885-4B58-9931-38BDC24A38C9Q40585039-8E4D1147-CD91-4909-9DDE-16B369F76157Q40602207-9CBED15B-B708-4C33-9B57-E69772BE60AEQ42157228-39E4C93B-C30E-48F5-906C-0F5260E7F0B5Q43002806-F340F984-3A99-4E36-A88C-31E20CFA4A43Q44402629-64FC9408-5FD6-4994-BED4-C3D8D4E4F0B6Q44402632-AA61635D-A446-4C35-876F-5E3F6149FFA6Q46584036-D9B57532-39E0-41A3-83D6-94237677EA0CQ57244789-F6A87096-98B7-41ED-844F-C768BA709B34Q57941803-958930C7-0EA3-4315-A385-9CEC0E31C2EA
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Serpins and other covalent protease inhibitors
@ast
Serpins and other covalent protease inhibitors
@en
Serpins and other covalent protease inhibitors
@nl
type
label
Serpins and other covalent protease inhibitors
@ast
Serpins and other covalent protease inhibitors
@en
Serpins and other covalent protease inhibitors
@nl
prefLabel
Serpins and other covalent protease inhibitors
@ast
Serpins and other covalent protease inhibitors
@en
Serpins and other covalent protease inhibitors
@nl
P1476
Serpins and other covalent protease inhibitors
@en
P2093
P356
10.1016/S0959-440X(01)00275-5
P407
P577
2001-12-01T00:00:00Z